Scott Ely

6.0k citations

89 papers · 3.4k indexed · h-index 28

Hematology top 1%
- Multiple Myeloma Research and Treatments 50
Genetics top 1%
- Chronic Lymphocytic Leukemia Research 8
Oncology top 2%
- Cancer Treatment and Pharmacology 12
- Cancer-related Molecular Pathways 10
Pathology and Forensic Medicine top 1%
- Lymphoma Diagnosis and Treatment 14
Immunology top 5%
- Immunotherapy and Immune Responses 10
Molecular Biology
- Protein Degradation and Inhibitors 21
- Ubiquitin and proteasome pathways 9

Co-authors: Selina Chen‐Kiang Rubén Niesvizky Daniel M. Knowles Ethel Cesarman John P. Leonard Morton Coleman Ornella Flore Amy Chadburn
Cited by: Hematology Genetics Oncology
Journals: Blood (38 papers)Journal of Clinical Oncology (8 papers)Clinical Cancer Research (3 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Scott Ely

87 papers receiving 3.4k citations

Peers

Countries citing papers authored by Scott Ely

Since Specialization

Citations

This map shows the geographic impact of Scott Ely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Ely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Ely more than expected).

Fields of papers citing papers by Scott Ely

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott Ely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Ely. The network helps show where Scott Ely may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Scott Ely, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Scott Ely Line = papers co-authored together Scott Ely links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients Clinical Lymphoma Myeloma & Leukemia ·Scott Ely,Peter A. Forsberg,郭润芳,Adriana Rossi,梁元錫,Roger Pearse,Karen Pekle,Tsung Yu,Morton Coleman,David Jayabalan,Maurizio Di Liberto,Selina Chen‐Kiang,Rubén Niesvizky,Tomer M. Mark	2017	6
2	Carfilzomib Induction with Lenalidomide and Clarithromycin Consolidation and Lenalidomide Maintenance (CarBiRD) for Multiple Myeloma (MM) Blood ·Peter A. Forsberg,Adriana Rossi,Roger Pearse,Tsung Yu,Karen Pekle,David Jayabalan,Scott Ely,Morton Coleman,John N. Allan,Rubén Niesvizky,Tomer M. Mark	2016	4
3	Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma Cancer Discovery ·David Chiron,Maurizio Di Liberto,Peter Martin,Xiangao Huang,Jeff P. Sharman,Pedro Blecua,Susan Mathew,Priyanka Vijay,Ken Eng,Siraj M. Ali,Amy J. Johnson,Betty Chang,Scott Ely,Olivier Elemento,Christopher E. Mason,John P. Leonard,Selina Chen‐Kiang	2014	204
4	Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques Current Hematologic Malignancy Reports ·Noa Biran,Scott Ely,Ajai Chari	2014	17
5	Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization Clinical Cancer Research ·Rubén Niesvizky,Tomer M. Mark,Maureen Ward,David Jayabalan,Roger Pearse,Megan Manco,Jessica Stern,Paul J. Christos,Lena Mathews,Tsiporah B. Shore,Faiza Zafar,Karen Pekle,Zhaoying Xiang,Scott Ely,仁清邰,Selina Chen‐Kiang,Morton Coleman,Maureen E. Lane	2013	20
6	IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease Modern Pathology ·Julia T. Geyer,Rubén Niesvizky,David Jayabalan,Susan Mathew,Shivakumar Subramaniyam,Alexander Geyer,Attilio Orazi,Scott Ely	2013	21
7	Induction of prolonged early G₁arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1 Cell Cycle ·David Chiron,Peter Martin,Maurizio Di Liberto,Xiangao Huang,Scott Ely,Brian J. Lannutti,John P. Leonard,Christopher E. Mason,Selina Chen‐Kiang	2013	59
8	MAGE-A Inhibits Apoptosis in Proliferating Myeloma Cells through Repression of Bax and Maintenance of Survivin Clinical Cancer Research ·Daijong Chung,Achim A. Jungbluth,Juan Pablo Escalera Antezana,Maurizio DiLiberto,Xiangao Huang,Sree Lekshmi,Valéria C.C. Andrade,Sayaka Muromachi,Scott Ely,Rubén Niesvizky,Roger Pearse,Morton Coleman,David Jayabalan,Nina Bhardwaj,Lloyd J. Old,Selina Chen‐Kiang,Hearn Jay Cho	2011	79
9	Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma Journal of Clinical Oncology ·Peter Martin,Amy Chadburn,Paul J. Christos,陆恒炜,Richard R. Furman,Jia Ruan,Rebecca Elstrom,Rubén Niesvizky,Scott Ely,Maurizio DiLiberto,Ari Melnick,Daniel M. Knowles,Selina Chen‐Kiang,Morton Coleman,John P. Leonard	2009	234
10	Personalized medicine: individualized care of cancer patients Translational research ·Scott Ely	2009	23
11	Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma British Journal of Haematology ·Tomer M. Mark,David Jayabalan,Morton Coleman,Roger Pearse,Y. Lynn Wang,Richard Lent,Paul J. Christos,Joong W. Lee,Yash Pal Agrawal,Susan Matthew,Scott Ely,Madhu Mazumdar,Ethel Cesarman,John P. Leonard,Richard R. Furman,Selina Chen‐Kiang,Rubén Niesvizky	2008	33
12	Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naïve patients undergoing front‐line lenalidomide and dexamethasone therapy British Journal of Haematology ·Rubén Niesvizky,Tara Naib,Paul J. Christos,David Jayabalan,Jessica Furst,Jessica Jalbrzikowski,Faiza Zafar,Tomer M. Mark,Richard Lent,Roger Pearse,Scott Ely,John P. Leonard,Madhu Mazumdar,Selina Chen‐Kiang,Morton Coleman	2007	68
13	A Novel Orally Active Small Molecule Potently Induces G1 Arrest in Primary Myeloma Cells and Prevents Tumor Growth by Specific Inhibition of Cyclin-Dependent Kinase 4/6 Cancer Research ·Linda B. Baughn,Maurizio Di Liberto,Kaida Wu,Peter L. Toogood,J Tusset Castellano,Rachel A. Gottschalk,Rubén Niesvizky,水村津与志,Scott Ely,Malcolm A.S. Moore,Selina Chen‐Kiang	2006	172
14	Osteopontin dysregulation and lytic bone lesions in multiple myeloma Hematological Oncology ·Davide F. Robbiani,Rebecca Parmer,Claudia Jimena Cuervo,Scott Ely,Marta Chesi,P. Leif Bergsagel	2006	27
15	Expression of CD56/Neural Cell Adhesion Molecule Correlates with the Presence of Lytic Bone Lesions in Multiple Myeloma and Distinguishes Myeloma from Monoclonal Gammopathy of Undetermined Significance and Lymphomas with Plasmacytoid Differentiation American Journal Of Pathology ·Scott Ely,Daniel M. Knowles	2002	126
16	CDK Inhibitor p18INK4c Is Required for the Generation of Functional Plasma Cells Immunity ·Michelle R. Tourigny,Josie Ursini‐Siegel,Hayyoung Lee,Kai‐Michael Toellner,Adam F. Cunningham,David S. Franklin,Scott Ely,Meihong Chen,F. Xiao‐Feng Qin,Yue Xiong,Ian C. M. MacLennan,Selina Chen‐Kiang	2002	88
17	Host Responses and Persistence of Vector Genome Following Intrabronchial Administration of an E1−E3− Adenovirus Gene Transfer Vector to Normal Individuals Molecular Therapy ·Ben‐Gary Harvey,Neil R. Hackett,Scott Ely,Ronald G. Crystal	2001	30
18	Cellular Immune Responses of Healthy Individuals to Intradermal Administration of an E1 ^- E3 ^- Adenovirus Gene Transfer Vector Human Gene Therapy ·Ben‐Gary Harvey,Stefan Worgall,Scott Ely,Philip L. Leopold,R G Crystal	1999	61
19	Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma arising in the subarachnoid space Human Pathology ·Scott Ely,James F. Powers,Drew Lewis,Sean Chang,เอกพันธ์ บางยี่ขัน,John O’Leary,Daniel M. Knowles	1999	18
20	Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus Nature ·Ornella Flore,Shahin Rafii,Scott Ely,John O’Leary,Elizabeth Hyjek,Ethel Cesarman	1998	333

About Scott Ely

Scott Ely is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine, having authored 89 papers that have together received 3.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (50 papers), Protein Degradation and Inhibitors (21 papers), Lymphoma Diagnosis and Treatment (14 papers), Cancer Treatment and Pharmacology (12 papers), Immunotherapy and Immune Responses (10 papers), Cancer-related Molecular Pathways (10 papers), Ubiquitin and proteasome pathways (9 papers) and Chronic Lymphocytic Leukemia Research (8 papers). The work is most often cited by research in Hematology (872 citations), Genetics (737 citations) and Oncology (1.6k citations). Scott Ely has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Selina Chen‐Kiang, Rubén Niesvizky, Daniel M. Knowles, Ethel Cesarman, John P. Leonard, Morton Coleman, Ornella Flore, Amy Chadburn, John O’Leary and Maurizio Di Liberto. Their work appears in journals such as Blood, Journal of Clinical Oncology, Clinical Cancer Research, British Journal of Haematology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact